Anticipated $-0.69 EPS for Wave Life Sciences Ltd. (WVE) as of May, 9

April 17, 2018 - By Nellie Rakes

Wave Life Sciences Ltd. (NASDAQ:WVE) Corporate Logo

On May, 9 WallStreet awaited Wave Life Sciences Ltd. (NASDAQ:WVE)’s earnings release, RTT reports. earnings per share of $-0.69 is 22.47 % up from 2017’s $-0.89 EPS. Wall Street now predicts -36.70 % EPS growth despite Wave Life Sciences Ltd. last quarter’s EPS of $-1.09. On during the last trading session the stock increased $0.15 or 0.37%, reaching $41.1.Currently Wave Life Sciences Ltd. is uptrending after 47.77% change in last April 17, 2017. WVE has 73,482 shares volume. WVE outperformed by 36.22% the S&P500.

WAVE Life Sciences Ltd., a genetic medicines company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform.The firm is valued at $1.20 billion. The firm is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.Currently it has negative earnings. It focuses on proprietary programs in neurology in the central nervous system and neuromuscular system.

Wave Life Sciences Ltd. (NASDAQ:WVE) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.